BTN News: Grifols, a well-known pharmaceutical company from Catalonia, and the Government of Andorra have decided to stop the plan for the Pyrenees Immunology Research Center. This choice was made after they ended their partnership early, as Grifols reported today. Now, the company will focus on growing its network of research centers in Europe and the United States, which has 13 centers, three of which are in Spain.
Grifols announced the creation of the Pyrenees Immunology Research Center in 2021. They planned to build the center in Ordino. Grifols owned 80% of the project, and the Andorran government, through Andorra Development and Investment (ADI), owned 20%. The center was expected to start working by 2023, but it faced many problems. There was local opposition, and Grifols was dealing with the fallout from the Gotham report scandal.
The Project Faced Many Challenges Including Local Opposition and a Scandal
The project never had strong local support. The Andorran government will now get back its investment of 200,000 euros, which Grifols will refund. The center was supposed to develop new treatments for immune system diseases and learn more about the human immune system. The project was to have an initial investment of 25 million euros, plus seven million euros every year for operating costs.
The Andorran Minister of Presidency, Economy, Work, and Housing, Conxita Marsol, said she was sorry the project could not continue but thanked Grifols for working with them. She also said that Andorra and Grifols might work together on other projects in the future.
Grifols Will Focus on Their Current Research Centers in Europe and the United States
Instead of the Ordino project, Grifols will use their current network of research centers. Company sources say this will make their research more efficient. This way, Grifols can keep working on new treatments without needing to build new facilities.
Grifols’ choice shows they want to use their current resources to push innovation. By focusing on their existing centers, they can speed up the research process and develop new treatments faster. This move shows Grifols is dedicated to advancing medical research while saving resources.
The Project Was Stopped Due to Local Opposition and the Gotham Report Scandal
The center in Ordino had problems from the start. Local opposition was a big reason the project did not move forward. Without local support, Grifols and the Andorran government could not continue. The Gotham report scandal also caused problems for Grifols and influenced their decision to stop the project.
Grifols and Andorra Are Open to Future Projects Together
Even though the project is stopped, Grifols and the Andorran government still want to work together in the future. They are open to new opportunities, which means there could be more projects together. This interest shows they still see value in working together.
Summary of Grifols and Andorra’s Decision to Stop the Immunology Research Center
Grifols and the Government of Andorra decided to stop the Pyrenees Immunology Research Center project. The project had many problems, including local opposition and the Gotham report scandal. Both Grifols and the Andorran government are hopeful about working together in the future. Grifols will now focus on their current network of research centers to keep advancing medical research. This decision helps them use their resources better and keep making progress in the field of immunology.
